Halozyme ( ($HALO) ) just unveiled an announcement. On November 12, 2025, Halozyme Therapeutics completed the sale of $1.5 billion in convertible ...

Good evening, and welcome to Dyadic International's Q3 2025 Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, November 12, 2025. I would now like to ...

By fusing enzyme fragments to antibodies, researchers from the Institute of Science Tokyo, in Japan, developed an innovative ...

The ability to respond to changing surroundings was once considered exclusive to complex living organisms. Then came ...

Previous attempts at building a chemical computer have been too simple, too rigid or too hard to scale, but an approach based ...

By fusing enzyme fragments to antibodies, researchers from Institute of Science Tokyo, Japan, developed an innovative enzyme ...

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's ...

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic ...

CompletedstrategicpivotfromR&Dfocustocommercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize ...

Cambridge, MA - Traditional bisulfite sequencing damages DNA, while enzyme-based alternatives are inconsistent. A novel methylation analysis method ...

Explore FPA Crescent Fund's Q3 2025 performance, which gained 5.54%. Get key insights on top contributors like Alphabet and ...

Total expenditure for the period under review added up to Rs 135.27 crore, up 19.2% YoY. This was primarily due to higher raw ...